- cafead Mar 31, 2023 at 10:22: AM
via
article source
- Skyrizi’s recently announced phase 3 clinical trial results to treat ulcerative colitis demonstrate that it is effective.
- An ulcerative colitis indication in the U.S. could be a blockbuster all on its own.
- AbbVie is attractively valued at the current share price.
article source